Pipeline: BPI-1178


Metastatic Breast Cancer


Mode of Action

Inhibition of CDK4/6 blocks phosphorylation of the human retinoblastoma protein (Rb), resulting in G1 cell cycle arrest and a shutdown of cell proliferation. Several solid tumor types overexpress Rb and are potential therapeutic areas for treatment with a CDK4/6 inhibitor, including metastatic breast cancer and non-small cell lung cancer.


  • Pre-clinical development ongoing
  • Efficacy & toxicology studies underway
  • Chinese CTA & US IND filing planned for Q2 2017

Click on the image to expand and view description.

CDK4/6 signaling in breast cancer